What is Genetron Holdings Limited (GTH) stock price today?

Genetron Holdings Limited (GTH) is currently trading at $4.03, up 0.12% today.

What is GTH P/E ratio?

Genetron Holdings Limited's P/E ratio is -0.95. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GTH return on equity (ROE)?

Genetron Holdings Limited's return on equity (ROE) is -100.92%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Genetron Holdings Limited's market cap?

Genetron Holdings Limited has a market capitalization of $127.29M.

NASDAQ · Medical - Diagnostics & Research

Genetron Holdings Limited (GTH) Stock

$4.03 +0.12% NASDAQ: GTH Healthcare

Valuation

Metric	Value
Price	$4.03
Market Cap	$127.29M
P/E Ratio	-0.95
P/B Ratio	1.54
P/S Ratio	1.32
EPS (TTM)	$-28.53
52-Week High	$4.05
52-Week Low	$2.08
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-100.92%
ROA	-90.62%
ROCE	-107.88%
Gross Margin	43.25%
Operating Margin	-97.07%
Net Margin	-135.84%
Debt/Equity	0.29
Current Ratio	1.82

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$225.0M	$323.0M	$424.0M	$532.0M	$651.0M
Operating Profit	$-233.0M	$-307.0M	$-254.0M	$-481.0M	$-632.0M
Net Profit	$-465.0M	$-321.0M	$-198.0M	$-438.0M	$-884.0M
EPS	$-6.73	$-4.65	$-3.29	$-4.76	$-28.53
Op Margin	-103.5%	-94.8%	-59.7%	-90.4%	-97.1%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$324.0M	$574.0M	$2.0B	$1.5B	$975.0M
Total Liabilities	$1.4B	$2.4B	$277.0M	$308.0M	$427.0M
Cash	$62.0M	$140.0M	$1.4B	$639.0M	$176.0M
Borrowings	$0	$68.0M	$124.0M	$74.0M	$159.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-201.0M	$-197.0M	$-301.0M	$-524.0M	$-460.0M
Investing Cash Flow	$124.0M	$-122.0M	$-135.0M	$-222.0M	$-170.0M
Financing Cash Flow	$49.0M	$317.0M	$1.7B	$-58.0M	$71.0M
Net Cash Flow	$20.0M	$78.0M	$1.2B	$-737.0M	$-463.0M
Free Cash Flow	$-248.0M	$-223.0M	$-351.0M	$-610.0M	$-542.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	-1.29
FCF Yield	-63.24%
Quick Ratio	1.71
Interest Coverage	-5.67
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ATYR	$0.49	+1.19%	-0.72	$47.62M	0.00%
DBTXDecibel Therapeutics, Inc.	$4.91	-0.81%	-1.95	$123.37M	0.00%
GENEGenetic Technologies Limited	$0.77	+0.00%	-0.40	$111.24M	0.00%
GRAYGraybug Vision, Inc.	$5.50	-10.80%	-4.23	$120.98M	0.00%
KNTEKinnate Biopharma Inc.	$2.65	-0.38%	-1.10	$124.99M	0.00%

About Genetron Holdings Limited

Genetron Holdings Limited (GTH) is a precision oncology company that specializes in cancer molecular profiling, utilizing advanced molecular biology and data science to enhance cancer treatment. The company delivers a range of services, including diagnosis, monitoring, and early screening, primarily through its proprietary laboratory-developed tests. Its product offerings encompass a variety of in-vitro diagnostic (IVD) solutions. These include the 8-gene lung cancer assay, an IVD product for lung cancer detection; the Genetron 3D biochip reading instrument; and the Genetron S5, a semiconductor-based next-generation sequencing (NGS) system that identifies nucleotides by detecting pH changes. Other key products are the Genetron Chef System, the production-scale Genetron S2000 sequencing platform, and Onco PanScan, a genomic profiling service for diverse solid tumors. Moreover, Genetron provides specialized assays such as the IDH1 and TERT gene assays for glioma, a fundamental thyroid assay for thyroid tumors, a platelet-derived growth factor receptor alpha assay for GIST cancer, and HCCscan, a qPCR-based assay designed to detect hepatocellular carcinoma. Beyond its direct services and products, the company offers genomics research and clinical development services, often in collaboration with biopharmaceutical companies globally. Genetron has also established a strategic partnership with JD Health to develop holistic solutions for comprehensive cancer management. The company was founded in 2015 and has its headquarters in Beijing, People's Republic of China.

Genetron Holdings Limited is headquartered in CN.

Genetron Holdings Limited (GTH) stock trades at $4.03 with a market capitalization of $127.29M. The stock is valued at a price-to-earnings (P/E) ratio of -0.95, price-to-book of 1.54, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $2.08 and $4.05, and currently trades at its 52-week high.

On profitability, Genetron Holdings Limited generates a return on equity (ROE) of -100.92%, return on capital employed of -107.88%, an operating margin of -97.07%, a net profit margin of -135.84%.

Official website: www.genetronhealth.com